BUSINESS● LOW1h ago · Sep 3, 2026, 3:31 PM
Ultragenyx slides amid multiple downgrades on trial setback for Angelman syndrome drug
Seeking Alpha Tech · global
Ultragenyx's stock has declined following multiple downgrades from analysts, which were prompted by a setback in a clinical trial for its Angelman syndrome drug. This highlights the financial impact of pharmaceutical research challenges.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowFor Senegal, after the IMF, the hardest part beginsJeune AfriqueBUSINESS34m agoCrowdStrike guides for 24.6% ARR in FY28 as it delivers at Fal.Con 2026: analystsSeeking Alpha TechBUSINESS40m agoHut 8 sells its Canadian managed cloud business to Opti9Seeking Alpha TechBUSINESS44m agoVirtus Convertible & Income Fund II declares $0.12 dividendSeeking Alpha Tech